Mesoblast (MESO) “provided an update on the progress of the U.S. commercial launch of Ryoncil, or remestemcel-L, for steroid-refractory acute graft-versus-host disease in pediatric patients 2 months and older and key upcoming milestones for its late-stage pipeline.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio